FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

SPOTLIGHT: FDA OKs expanded access for stem cell therapy


Osiris Therapeutics has won approval for an expanded access treatment program for Prochymal, making the Phase III stem cell therapy for graft-vs-host-disease available to children. Osiris release

More stories about Phase III  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 10 + 10?
To combat spam, please solve the math question above.